Synonym
UDM-001651; UDM 001651; UDM001651; UDM-1651; UDM 1651; UDM1651;
IUPAC/Chemical Name
6-(4-((3-(Benzyloxy)benzyl)oxy)-6-methoxybenzofuran-2-yl)-2-methoxyimidazo[2,1-b][1,3,4]thiadiazole
InChi Key
LFOIDLOIBZFWDO-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H23N3O5S/c1-32-21-12-24(35-17-19-9-6-10-20(11-19)34-16-18-7-4-3-5-8-18)22-14-26(36-25(22)13-21)23-15-31-27(29-23)37-28(30-31)33-2/h3-15H,16-17H2,1-2H3
SMILES Code
COC1=NN2C(S1)=NC(C3=CC4=C(OCC5=CC=CC(OCC6=CC=CC=C6)=C5)C=C(OC)C=C4O3)=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Atherothrombotic cardiovascular and cerebrovascular diseases are the leading cause of morbidity and mortality in developed countries and claim more lives each year than cancer in the United States.1 Atherothrombotic diseases, such as acute coronary syndrome and stroke, originate with a gradual buildup of plaque in the arterial wall. The eventual rupture of an atherosclerotic plaque exposes a prothrombotic milieu to the blood and activates platelets at the site of the injury, leading to the formation of a potentially occlusive thrombus and subsequent ischemia.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
513.57
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel
A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ,
Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang
Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM,
Priestley ES, Marinier A. Discovery of Potent Protease-Activated Receptor 4
Antagonists with in Vivo Antithrombotic Efficacy. J Med Chem. 2019 Aug 5. doi:
10.1021/acs.jmedchem.9b00186. [Epub ahead of print] PubMed PMID: 31246024.
